Se­lec­ta Bio­sciences is nar­row­ing its fo­cus

Se­lec­ta Bio­sciences an­nounced Thurs­day that it will stop in­vest­ment in most of its pipeline as­sets ex­cept for a treat­ment for chron­ic re­frac­to­ry gout li­censed to …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER